⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TAK News
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
prnewswire.com
TAK
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
businesswire.com
TAK
PM360 Announces 2026 Lifetime Achievement Award Honoree, CMO of the Year, and Brand Champions
prnewswire.com
LLY
JNJ
BMY
MRK
REGN
KURA
BMRN
TAK
VRTX
GSK
AZN
AMGN
ABBV
Polpharma Biologics annuncia che la FDA e l'EMA hanno accettato le domande di revisione relative a PB016, il candidato biosimilare di vedolizumab dell'azienda
businesswire.com
TAK
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
businesswire.com
TAK
武田制药Zasocitinib（泽索昔替尼）在3期银屑病研究中
businesswire.com
TAK
武田制药Zasocitinib（泽索昔替尼）在3期银屑病研究中 显示出全身一致的高皮损清除率，包括难治及高影响部位
businesswire.com
TAK
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
globenewswire.com
BMY
PFE
AMGN
NVS
MRK
LLY
GILD
AZN
TAK
JNJ
ABBV
CRSP
MOD
ARVN
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
businesswire.com
TAK
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
businesswire.com
TAK